Searching for synthetic lethality in cancer

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 34-41

  Brough, Rachel ^a   Frankum, Jessica R ^a   Costa Cabral, Sara ^a   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX; B RAF KINASE; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; K RAS PROTEIN; LAPATINIB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MSH2; SMALL INTERFERING RNA; TRASTUZUMAB;

BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LETHALITY; LUNG CANCER; MELANOMA; NEOPLASM; NONHUMAN; ONCOGENE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG DESIGN; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79551629227     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.10.009     Document Type: Review

References (47)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Lord C.J., Ashworth A Biology-driven cancer drug development: back to the future. BMC Biol 2010, 8:38.
3. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem Biol 1999, 6:71-83.
4. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
5. Simons A.H., Dafni N., Dotan I., Oron Y., Canaani D. Genetic synthetic lethality screen at the single gene level in cultured human cells. Nucleic Acids Res 2001, 29:E100.
6. Hartman JLt, Garvik B., Hartwell L. Principles for the buffering of genetic variation. Science 2001, 291:1001-1004.
7. Ye P., Peyser B.D., Pan X., Boeke J.D., Spencer F.A., Bader J.S. Gene function prediction from congruent synthetic lethal interactions in yeast. Mol Syst Biol 2005, 1:0026.
8. Tong A.H., Lesage G., Bader G.D., Ding H., Xu H., Xin X., Young J., Berriz G.F., Brost R.L., Chang M., et al. Global mapping of the yeast genetic interaction network. Science 2004, 303:808-813.
9. Lucchesi J.C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 1968, 59:37-44.
10. Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946, 31:269-290.
11. Sturtevant A.H. A highly specific complementary lethal system in Drosophila melanogaster. Genetics 1956, 41:118-123.
12. Lehner B., Crombie C., Tischler J., Fortunato A., Fraser A.G. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat Genet 2006, 38:896-903.
13. Byrne A.B., Weirauch M.T., Wong V., Koeva M., Dixon S.J., Stuart J.M., Roy P.J. A global analysis of genetic interactions in Caenorhabditis elegans. J Biol 2007, 6:8.
14. Ooi S.L., Pan X., Peyser B.D., Ye P., Meluh P.B., Yuan D.S., Irizarry R.A., Bader J.S., Spencer F.A., Boeke J.D. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet 2006, 22:56-63.
15. Simon J.A., Szankasi P., Nguyen D.K., Ludlow C., Dunstan H.M., Roberts C.J., Jensen E.L., Hartwell L.H., Friend S.H. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000, 60:328-333.
16. Tong A.H., Evangelista M., Parsons A.B., Xu H., Bader G.D., Page N., Robinson M., Raghibizadeh S., Hogue C.W., Bussey H., et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294:2364-2368.
17. Typas A., Nichols R.J., Siegele D.A., Shales M., Collins S.R., Lim B., Braberg H., Yamamoto N., Takeuchi R., Wanner B.L., et al. High-throughput, quantitative analyses of genetic interactions in E. coli. Nat Methods 2008, 5:781-787.
18. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007, 6:556-568.
19. Ooi S.L., Shoemaker D.D., Boeke J.D. DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray. Nat Genet 2003, 35:277-286.
20. Roguev A., Wiren M., Weissman J.S., Krogan N.J. High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe. Nat Methods 2007, 4:861-866.
21. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
22. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
23. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790.
24. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
25. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
26. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
27. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., Waldman T., Lord C.J., Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
28. Giaever G., Chu A.M., Ni L., Connelly C., Riles L., Veronneau S., Dow S., Lucau-Danila A., Anderson K., Andre B., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002, 418:387-391.
29. Winzeler E.A., Shoemaker D.D., Astromoff A., Liang H., Anderson K., Andre B., Bangham R., Benito R., Boeke J.D., Bussey H., et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999, 285:901-906.
30. Kamath R.S., Fraser A.G., Dong Y., Poulin G., Durbin R., Gotta M., Kanapin A., Le Bot N., Moreno S., Sohrmann M., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421:231-237.
31. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698.
32. Gottipati P., Vischioni B., Schultz N., Solomons J., Bryant H.E., Djureinovic T., Issaeva N., Sleeth K., Sharma R.A., Helleday T Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010, 70:5389-5398.
33. Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka S., Kay E., Lord C.J., Ashworth A DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
34. Dong Y., Li A., Wang J., Weber J.D., Michel L.S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 2010, 70:5465-5474.
35. Bernards R., Brummelkamp T.R., Beijersbergen R.L. shRNA libraries and their use in cancer genetics. Nat Methods 2006, 3:701-706.
36. Iorns E., Lord C.J., Grigoriadis A., McDonald S., Fenwick K., Mackay A., Mein C.A., Natrajan R., Savage K., Tamber N., et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009, 4:e5120.
37. Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009, 1:323-337.
38. Turner N.C., Lord C.J., Iorns E., Brough R., Swift S., Elliott R., Rayter S., Tutt A.N., Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008, 27:1368-1377.
39. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7:2010-2019.
40. Iorns E., Turner N.C., Elliott R., Syed N., Garrone O., Gasco M., Tutt A.N., Crook T., Lord C.J., Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
41. Echeverri C.J., Beachy P.A., Baum B., Boutros M., Buchholz F., Chanda S.K., Downward J., Ellenberg J., Fraser A.G., Hacohen N., et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006, 3:777-779.
42. Iorns E., Lord C.J., Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 2009, 417:361-370.
43. Weiss W.A., Taylor S.S., Shokat K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 2007, 3:739-744.
44. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
45. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
46. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
47. Wang Y., Ngo V.N., Marani M., Yang Y., Wright G., Staudt L.M., Downward J. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.